⚖️ Obesity Therapeutic Vaccine Tracker Dashboard

Updated July 2026. Reality check on the field: No obesity vaccine is currently in advanced clinical development. Anti-ghrelin and anti-leptin vaccines advanced through animal and small early human studies over the past two decades but did not produce robust or durable weight loss and have largely been abandoned commercially. The obesity treatment landscape is instead dominated by GLP-1 receptor agonists (semaglutide/Wegovy, tirzepatide/Zepbound) and the newer wave of agents that received major 2026 approvals: Wegovy HD (semaglutide 7.2 mg once-weekly, FDA approved March 19, 2026 — 20.7% mean weight loss at 72 weeks in STEP UP trial), orforglipron/Foundayo (Eli Lilly, oral GLP-1, FDA approved April 1, 2026), and CagriSema (Novo Nordisk cagrilintide + semaglutide) under FDA review in 2026. Vaccine-based hormone neutralization remains a scientifically interesting but stalled concept. This tracker continues to monitor any renewed vaccine-focused efforts in obesity, but readers should understand that current standard-of-care obesity pharmacotherapy is not vaccination.

Comprehensive tracking of obesity therapeutic vaccine development targeting hunger hormones (ghrelin), satiety signals (leptin), and metabolic regulators (GIP/GLP-1). Obesity affects 42% of US adults (890 million globally) with $173 billion annual healthcare costs. Revolutionary immunotherapy approaches aim for long-term weight management through antibody-mediated hormone neutralization. Multiple Phase 1-3 trials target ghrelin (hunger hormone), GIP (glucose-dependent insulinotropic polypeptide), and metabolic pathways. Complementary to lifestyle interventions and emerging medications.

⚠️ GLOBAL OBESITY EPIDEMIC:

Obesity affects 42% of US adults (138 million), 890 million globally. Leading risk factor for type 2 diabetes, cardiovascular disease, certain cancers, sleep apnea, osteoarthritis. $173 billion annual US healthcare costs, $1.7 trillion global economic impact. Current treatments (diet/exercise, medications, bariatric surgery) have limited long-term success. Therapeutic vaccines offer novel approach targeting biological drivers of weight gain.

Obesity Vaccines by Development Phase